Last week’s other top NASDAQ biotech stocks were Sesen Bio, Bio-Path Holdings, LogicBio Therapeutics and Merus.
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) closed last Thursday (April 18) at 3,286.56, roughly flat from the previous day but down from its close of 3,470.95 on Monday (April 15).
Despite a short trading week, several NASDAQ-listed biotech and pharmaceutical companies recorded impressive share price gains over the course of the four-day period, with Mustang Bio (NASDAQ:MBIO) taking the lead by far with a spike of over 75 percent.
The following five stocks saw the biggest share price gains last week:
- Mustang Bio
- Sesen Bio (NASDAQ:SESN)
- Bio-Path Holdings (NASDAQ:BPTH)
- LogicBio Therapeutics (NASDAQ:LOGC)
- Merus (NASDAQ:MRUS)
Mustang Bio is focused on treating hematologic cancers, solid tumors and rare genetic diseases using advancements in cell and gene therapies. The company’s strategy is to minimize development risk by in-licensing therapeutic candidates from leading institutions.
Last Wednesday (April 17), the biopharmaceutical firm announced the publication of data from a Phase 1/2 clinical trial of a lentiviral gene therapy used to treat infants with XSCID, also known as “bubble boy disease.” Results were released for eight of the 10 infants participating in the trial, and according to the company those eight have been cured. All are under two years old.
Researchers at St. Jude Children’s Research Hospital developed the cure and treated the infants; Mustang is developing the gene therapy for commercial use. The company’s share price leaped 75.16 percent to reach US$5.44 at the close of trading last week.
Sesen Bio is using fusion protein medicines to treat cancer. The clinical-stage company’s lead program is Vicinium, which is now now in a Phase 3 registration trial geared at treating high-grade non-muscle invasive bladder cancer.
Last week, the company’s share price jumped 21.62 percent to land at US$1.18. It did not release any news during the period, with its last publication coming on March 4, when it shared its Q4 and full-year operating results for 2018.
Bio-Path Holdings’ goal is to use targeted therapies to treat difficult cancers like acute myeloid leukemia (AML) and chronic myeloid leukemia. A Phase 2 trial is currently in the works for its lead candidate, BP1001. The trial has 54 participants, all with previously untreated AML. The company’s other candidates are BP1002 and BP1003.
Bio-Path’s share price rose 16.76 percent last week to close at US$19.02, although it did not put out any news. It last shared news on April 4, when it presented pre-clinical data on BP1003.
Genome editing company LogicBio Therapeutics aims to treat pediatric patients with rare diseases, with its initial focus being rare liver disorders. Its proprietary GeneRide technology allows it to edit the human genome while sidestepping risks often associated with this process.
The company saw a share price increase of 16.71 percent to finish last week at US$12.15. It did not provide any updates during that time, with its last news coming on April 1, when it released its Q4 and full-year financial results for 2018.
Merus is a clinical-stage immuno-oncology company that uses its bispecific antibody therapeutics, called Biclonics, to treat cancer. It has five drug candidates in its pipeline in various stages of development.
The company did not release any news last week, but its share price closed the period up 15.7 percent at US$15.70. Its most recent news came when it released its financial results for 2018 on April 3. Merus also provided a business update at that time.
Data for the 5 Top NASDAQ Biotech Stocks articles is retrieved each Friday at 1:00 p.m. EDT using TradingView‘s stock screener. Only companies with a market capitalization greater than $10 million and lower than $500 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Don’t forget to follow us at @INN_LifeScience for real-time updates!
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.